Referanslar

1. Lee CG, Lim YJ, Park SJ, Jang BI, Choi SR, Kim JK, et al. The clinical features and treatment modality of esophageal neuroendocrine tumors: A multicenter study in Korea. BMC Cancer. 2014;14(1):1-7. [Crossref]  [PubMed]  [PMC]
2. Deng HY, Ni PZ, Wang YC, Wang WP, Chen LQ. Neuroendocrine carcinoma of the esophagus: Clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac Dis. 2016;8(6):1250-6. [Crossref]  [PubMed]  [PMC]
3. Giannetta E, Guarnotta V, Rota F, de Cicco F, Grillo F, Colao A, et al. A rare rarity: Neuroendocrine tumor of the esopha gus. Crit Rev Oncol Hematol. 2019;137(February):92-107. [Crossref]  [PubMed]
4. Schizas D, Mastoraki A, Kirkilesis GI, Sioulas AD, Papanikolaou IS, Misiakos EP, et al. Neuroendocrine Tumors of the Esophagus: State of the Art in Diagnostic and Therapeutic Management. J Gastrointest Cancer. 2017;48(4):299-304. [Crossref]  [PubMed]
5. Yazici C, Boulay BR. Evolving role of the endoscopist in management of gastrointestinal neuroendocrine tumors. World J Gastroenterol. 2017;23(27):4847-55. [Crossref]  [PubMed]  [PMC]
6. Ye L, Lu H, Wu L, Zhang L, Shi H, Wu HM, et al. The clinicopathologic features and prognosis of esophageal neuroendocrine carcinomas: A single-center study of 53 resection cases. BMC Cancer. 2019;19(1):1-8. [Crossref]  [PubMed]  [PMC]
7. Gopakumar H, Jahagirdar V, Koyi J, Dahiya DS, Goyal H, Sharma NR, et al. Role of Advanced Gastrointestinal Endoscopy in the Comprehensive Management of Neuroendocrine Neoplasms. Cancers (Basel). 2023;15(16):1-23. [Crossref]  [PubMed]  [PMC]
8. Yagi M, Abe Y, Sasaki Y, Nomura E, Sato T, Iwano D, et al. Esophageal carcinoid tumor treated by endoscopic resection. Dig Endosc. 2015;27(4):527-30. [Crossref]  [PubMed]
9. Grant M, Rea DW. Adjuvant endocrine therapy for postmenopausal women with early stage breast cancer [Internet]. Vol. 1, Therapy. 2004;305-18. [cited 2020 Apr 25]. [Crossref]
10. Deprez PH, Moons LMG, O'Toole D, Gincul R, Seicean A, Pimentel-Nunes P, et al. Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2022;54(4):412-29. [Crossref]  [PubMed]
11. Ma Z, Cai H, Cui Y. Progress in the treatment of esophageal neuroendocrine carcinoma. Tumor Biol. 2017;39(6):0-5. [Crossref]  [PubMed]
12. Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A, Ramage JK. Review article: The investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther. 2014;39(10):1071-84. [Crossref]  [PubMed]
13. Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and adrenal tumors, version 2.2021. JNCCN J Natl Compr Cancer Netw. 2021;19(7):839-67.
14. Exarchou K, Howes N, Pritchard DM. Systematic review: management of localised low-grade upper gastrointestinal neuroendocrine tumours. Aliment Pharmacol Ther. 2020;51(12):1247-67. [Crossref]  [PubMed]
15. Min BH, Hong M, Lee JH, Rhee PL, Sohn TS, Kim S, et al. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours. Br J Surg. 2018;105(11):1480-6. [Crossref]  [PubMed]
16. Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770-86. [Crossref]  [PubMed]  [PMC]
17. Sato Y. Endoscopic diagnosis and management of type I neuroendocrine tumors. World J Gastrointest Endosc. 2015;7(4):346. [Crossref]  [PubMed]  [PMC]
18. Iabichino G, Di Leo M, Arena M, Rubis Passoni GG, Morandi E, Turpini F, et al. Diagnosis, treatment, and current concepts in the endoscopic management of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol. 2022;14;28(34):4943-4958. [Crossref]  [PubMed]  [PMC]
19. de Mestier L, Lepage C, Baudin E, Coriat R, Courbon F, Couvelard A, et al. Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis [Internet]. 2020;52(5):473-92. [Crossref]  [PubMed]
20. Vanoli A, La Rosa S, Miceli E, Klersy C, Maragliano R, Capuano F, et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: Analysis of 200 cases with extended follow-up. Neuroendocrinology. 2018;107(2):114-26. [Crossref]  [PubMed]
21. Panzuto F, Ramage J, Pritchard DM, van Velthuysen MLF, Schrader J, Begum N, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. J Neuroendocrinol. 2023;35(8):1-14. [Crossref]  [PubMed]
22. Zilli A, Arcidiacono PG, Conte D, Massironi S. Clinical impact of endoscopic ultrasonography on the management of neuroendocrine tumors: lights and shadows. Dig Liver Dis [Internet]. 2018;50(1):6-14. [Crossref]  [PubMed]
23. Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019;12. [Crossref]  [PubMed]  [PMC]
24. Panzuto F, Magi L, Esposito G, Rinzivillo M, Annibale B. Comparison of endoscopic techniques in the management of type i gastric neuroendocrine neoplasia: A systematic review. Gastroenterol Res Pract. 2021;2021. [Crossref]  [PubMed]  [PMC]
25. Kim HH, Kim GH, Kim JH, Choi MG, Song GA, Kim SE. The efficacy of endoscopic submucosal dissection of type i gastric carcinoid tumors compared with conventional endoscopic mucosal resection. Gastroenterol Res Pract. 2014;2014. [Crossref]  [PubMed]  [PMC]
26. Noh JH, Kim DH, Yoon H, Hsing LC, Na HK, Ahn JY, et al. Clinical Outcomes of Endoscopic Treatment for Type 1 Gastric Neuroendocrine Tumor. J Gastrointest Surg. 2021;25(10):2495-502. [Crossref]  [PubMed]
27. Kulke MH, Shah MH, Benson Iii AB, Bergsland E, Berlin JD, Blaszkowsky LS, et al. Neuroendocrine Tumors, Version 1.2015 Clinical Practice Guidelines in Oncology. JNCCN-Journal Natl Compr Cancer Netw |. 2015;13(1):78-108. [Crossref]
28. Exarchou K, Kamieniarz L, Tsoli M, Victor A, Oleinikov K, Khan MS, et al. Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms? Endocrine [Internet]. 2021;74(2):421-9. [Crossref]  [PubMed]
29. Chin JL, O'Connell J, Muldoon C, Swan N, Reynolds JV, Ravi N, et al. Selective Resection of Type 1 Gastric Neuroendocrine Neoplasms and the Risk of Progression in an Endoscopic Surveillance Programme. Dig Surg. 2021;38(1):38-45. [Crossref]  [PubMed]
30. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Port. Endoscopy. 2019;51(4):365-88. [Crossref]  [PubMed]
31. Thakker RV, Newey PJ, Walls G V., Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011. [Crossref]  [PubMed]
32. Sato Y, Hashimoto S, Mizuno KI, Takeuchi M, Terai S. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol. 2016;22(30):6817-28. [Crossref]  [PubMed]  [PMC]
33. Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol. 2005;19(5 SPEC. ISS.):675-97. [Crossref]  [PubMed]
34. Randle RW, Ahmed S, Newman NA, Clark CJ. Clinical Outcomes for Neuroendocrine Tumors of the Duodenum and Ampulla of Vater:A Population-Based Study. J Gastrointest Surg. 2014;18(2):354-62. [Crossref]  [PubMed]
35. Pavlovic Markovic A, Rösch T, Alempijevic T, Krstic M, Tomic D, Dugalic P, et al. Endoscopic ultrasound for differential diagnosis of duodenal lesions. Ultraschall der Medizin. 2012;33(7):210-7. [Crossref]  [PubMed]
36. Brito HP, Torres IT, Turke KC, Parada AA, Waisberg J, Botelho RV. Comparison of endoscopic resection techniques for duodenal neuroendocrine tumors: systematic review. Endosc Int Open. 2021;09(08):E1214-21. [Crossref]  [PubMed]  [PMC]
37. Tsujimoto H, Ichikura T, Nagao S, Sato T, Ono S, Aiko S, et al. Minimally invasive surgery for resection of duodenal carcinoid tumors: Endoscopic full-thickness resection under laparoscopic observation. Surg Endosc. 2010;24(2):471-5. [Crossref]  [PubMed]
38. Dwyer S, Mok S. Endoscopic full-thickness resection of well-differentiated T2 neuroendocrine tumors in the duodenal bulb: a case series. VideoGIE [Internet]. 2022;7(5):196-9. [Crossref]  [PubMed]  [PMC]
39. Hawa F, Sako Z, Nguyen T, Catanzaro AT, Zolotarevsky E, Bartley AN, et al. The band and slough technique is effective for management of diminutive type 1 gastric and duodenal neuroendocrine tumors. Endosc Int Open. 2020;08(06):E717-21. [Crossref]  [PubMed]  [PMC]
40. Lee SW, Sung JK, Cho YS, Bang KB, Kang SH, Kim KB, et al. Comparisons of therapeutic outcomes in patients with nonampullary duodenal neuroendocrine tumors (NADNETs): A multicenter retrospective study. Medicine (Baltimore). 2019;98(26):e16154. [Crossref]  [PubMed]  [PMC]
41. Gincul R, Ponchon T, Napoleon B, Scoazec JY, Guillaud O, Saurin JC, et al. Endoscopic treatment of sporadic small duodenal and ampullary neuroendocrine tumors. Endoscopy. 2016;48(11):979-86. [Crossref]  [PubMed]
42. Shimai S, Yamamoto K, Sofuni A, Tsuchiya T, Ishii K, Tanaka R, et al. Three cases of ampullary neuroendocrine tumor treated by endoscopic papillectomy: A case report and literature review. Intern Med. 2020;59(19):2369-74. [Crossref]  [PubMed]  [PMC]
43. Mandair D, Kamieniarz L, Pizanias M, Weickert MO, Narayan A, O'Mahony LF, et al. Diagnostic features and management options for duodenal neuroendocrine neoplasms: a retrospective, multi-centre study. Sci Rep [Internet]. 2022;12(1):1-9. [Crossref]  [PubMed]  [PMC]
44. Scott AT, Howe JR. Management of small bowel neuroendocrine tumors. J Oncol Pract. 2018;14(8):471-82. [Crossref]  [PubMed]  [PMC]
45. Scott AT, Howe JR. Management of Small Bowel Neuroendocrine Tumors. Surg Oncol Clin N Am [Internet]. 2020;29(2):223-41. [Crossref]  [PubMed]
46. Hirabayashi K, Zamboni G, Nishi T, Tanaka A, Kajiwara H, Nakamura N. Histopathology of gastrointestinal neuroendocrine neoplasms. Front Oncol. 2013;3 JAN(January):1-12. [Crossref]  [PubMed]  [PMC]
47. Sivero L, Telesca DA, Ruggiero S, Russo T, Amato M, Bianco T, et al. Endoscopic diagnosis and treatment of neuroendocrine tumors of the digestive system. Open Med. 2016;11(1):369-73. [Crossref]  [PubMed]  [PMC]
48. Kitano M, Kudo M, Yamao K, Takagi T, Sakamoto H, Komaki T, et al. Characterization of small solid tumors in the pancreas: The value of contrast-enhanced harmonic endoscopic ultrasonography. Am J Gastroenterol [Internet]. 2012;107(2):303-10. [Crossref]  [PubMed]
49. Caplin M, Sundin A, Nillson O, Baum RP, Klose KJ, Kelestimur F, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology. 2012;95(2):88-97. [Crossref]  [PubMed]
50. Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, et al. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):139-43. [Crossref]  [PubMed]
51. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934-59. [Crossref]  [PubMed]
52. Reumkens A, Sastrowijoto P, Grabsch HI, Goudkade D, le Clercq C, Bakker M, et al. Epidemiological, clinical and endoscopic characteristics of colorectal neuroendocrine neoplasms: a population-based study in the Netherlands. Endosc Int Open. 2022;10(07):E940-51. [Crossref]  [PubMed]  [PMC]
53. Sauer M, Hildenbrand R, Oyama T, Sido B, Yahagi N, Dumoulin F. Endoscopic submucosal dissection for flat or sessile colorectal neoplasia > 20 mm: A European single-center series of 182 cases. Endosc Int Open. 2016;04(08):E895900. [Crossref]  [PubMed]  [PMC]
54. Takezawa T, Hayashi Y, Shinozaki S, Sagara Y, Okada M, Kobayashi Y, et al. The pocket-creation method facilitates colonic endoscopic submucosal dissection (with video). Gastrointest Endosc [Internet]. 2019;89(5):1045-53. [Crossref]  [PubMed]
55. Ismail MS, Bahdi F, Mercado MO, Habazi R, Alexander A, Prabhu S, et al. ESD with double-balloon endoluminal intervention platform versus standard ESD for management of colon polyps. Endosc Int Open. 2020;08(10):E1273-9. [Crossref]  [PubMed]  [PMC]
56. Ramos-Zabala F, García-Mayor M, Domínguez-Pino A, Alzina-Pérez A, Moreno-Almazán L. Combination of immersion in saline solution, pocket-creation method, water-jet hydrodissection, and hybrid knife "probe mode" simplifies endoscopic submucosal dissection in giant rectal polyp. VideoGIE [Internet]. 2019;4(10):478-80. [Crossref]  [PubMed]  [PMC]
57. Nets NT, Anthony LB, Strosberg JR, Klimstra ÞDS, Maples WJ, Dorisio TMO, et al. The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal. Pancreas. 2010;39(6):767-74. [Crossref]  [PubMed]
58. Moertel CG, Dockerty MB, Judd ES. Carcinoid tumors of the vermiform appendix. Cancer. 1968;21(2):270-8. [Crossref]  [PubMed]
59. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: Well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39(6):753-66. [Crossref]  [PubMed]
60. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157-76. [Crossref]  [PubMed]
61. Heller DR, Jean RA, Luo J, Kurbatov V, Grisotti G, Jacobs D, et al. Practice Patterns and Guideline Non-Adherence in Surgical Management of Appendiceal Carcinoid Tumors. J Am Coll Surg [Internet]. 2019;228(6):839-51. [Crossref]  [PubMed]  [PMC]
62. Veyre F, Lambin T, Fine C, Fenouil T, Rostain F, Walter T, et al. Endoscopic characterization of rectal neuroendocrine tumors with virtual chromoendoscopy: Differences between benign and malignant lesions. Endoscopy. 2021;53(6):E215-6. [Crossref]  [PubMed]
63. Gallo C, Invernizzi P, Massironi S, Rossi RE, Cavalcoli F, Barbaro F, et al. Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance. World J Gastroenterol. 2022;28(11):1123-38. [Crossref]  [PubMed]  [PMC]
64. de Mestier L, Lorenzo D, Fine C, Cros J, Hentic O, Walter T, et al. Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab. 2019;33(5). [Crossref]  [PubMed]
65. McDermott FD, Heeney A, Courtney D, Mohan H, Winter D. Rectal carcinoids: A systematic review. Surg Endosc. 2014;28(7):2020-6. [Crossref]  [PubMed]
66. Chen L, Guo Y, Zhang Y, Liu M, Zhang Y, Lin Y, et al. Development of a novel scoring system based on endoscopic appearance for management of rectal neuroendocrine tumors. Endoscopy. 2021;53(7):702-9. [Crossref]  [PubMed]
67. Moon CM, Huh KC, Jung SA, Park D Il, Kim WH, Jung HM, et al. Long-Term Clinical Outcomes of Rectal Neuroendocrine Tumors According to the Pathologic Status After Initial Endoscopic Resection: A KASID Multicenter Study. Am J Gastroenterol [Internet]. 2016;111(9):1276-85. [Crossref]  [PubMed]
68. Park CH, Cheon JH, Kim JO, Shin JE, Jang BI, Shin SJ, et al. Criteria for decision making after endoscopic resection of well-differentiated rectal carcinoids with regard to potential lymphatic spread. Endoscopy. 2011;43(9):790-5. [Crossref]  [PubMed]
69. Cazacu I, Singh B, Luzuriaga Chavez A, Koduru P, Ejaz S, Weston B, et al. EUS and EUS-guided FNA/core biopsies in the evaluation of subepithelial lesions of the lower gastrointestinal tract: 10-year experience. Endosc Ultrasound. 2020;9(5):329-36. [Crossref]  [PubMed]  [PMC]
70. Chen HT, Xu GQ, Teng XD, Chen YP, Chen LH, Li YM. Diagnostic accuracy of endoscopic ultrasonography for rectal neuroendocrine neoplasms. World J Gastroenterol. 2014;20(30):10470-7. [Crossref]  [PubMed]  [PMC]
71. Rinke A, Ambrosini V, Dromain C, Garcia-Carbonero R, Haji A, Koumarianou A, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J Neuroendocrinol. 2023;35(6):1-15. [Crossref]  [PubMed]
72. Kamp K, Damhuis RAM, Feelders RA, De Herder WW. Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas. Endocr Relat Cancer. 2012;19(1):95-9. [Crossref]  [PubMed]
73. Son HJ, Sohn DK, Hong CW, Han KS, Kim BC, Park JW, et al. Factors associated with complete local excision of small rectal carcinoid tumor. Int J Colorectal Dis. 2013;28(1):57-61. [Crossref]  [PubMed]
74. Bang BW, Park JS, Kim HK, Shin YW, Kwon KS, Kim JM. Endoscopic Resection for Small Rectal Neuroendocrine Tumors: Comparison of Endoscopic Submucosal Resection with Band Ligation and Endoscopic Submucosal Dissection. Gastroenterol Res Pract. 2016;2016. [Crossref]  [PubMed]  [PMC]
75. Park SB, Kim HW, Kang DH, Choi CW, Kim SJ, Nam HS. Advantage of endoscopic mucosal resection with a cap for rectal neuroendocrine tumors. World J Gastroenterol. 2015;21(31):9387-93. [Crossref]  [PubMed]  [PMC]
76. Zheng JC, Zheng K, Zhao S, Wang ZN, Xu HM, Jiang CG. Efficacy and safety of modified endoscopic mucosal resection for rectal neuroendocrine tumors: A meta-analysis. Z Gastroenterol. 2020;58(2):137-45. [Crossref]  [PubMed]
77. Wang X, Xiang L, Li A, Han Z, Li Y, Wang Y, et al. Endoscopic submucosal dissection for the treatment of rectal carcinoid tumors 7-16 mm in diameter. Int J Colorectal Dis. 2015;30(3):375-80. [Crossref]  [PubMed]
78. Huang J-L, Gan R-Y, Chen Z-H, Gao R-Y, Li D-F, Wang L-S, et al. Endoscopic mucosal resection with double band ligation versus endoscopic submucosal dissection for small rectal neuroendocrine tumors. World J Gastrointest Surg. 2023;15(3):440-9. [Crossref]  [PubMed]  [PMC]
79. Park SS, Han KS, Kim B, Chang Kim B, Hong CW, Sohn DK, et al. Comparison of underwater endoscopic mucosal resection and endoscopic submucosal dissection of rectal neuroendocrine tumors (with videos). Gastrointest Endosc [Internet]. 2020;91(5):1164-1171.e2. [Crossref]  [PubMed]
80. Gleeson FC, Levy MJ, Dozois EJ, Larson DW, Wong Kee Song LM, Boardman LA. Endoscopically identified well-differentiated rectal carcinoid tumors: Impact of tumor size on the natural history and outcomes. Gastrointest Endosc [Internet]. 2014;80(1):144-51. [Crossref]  [PubMed]
81. Jin R, Bai X, Xu T, Wu X, Wang Q, Li J. Comparison of the efficacy of endoscopic submucosal dissection and transanal endoscopic microsurgery in the treatment of rectal neuroendocrine tumors ≤ 2 cm. Front Endocrinol (Lausanne). 2023;13(January):1-10. [Crossref]  [PubMed]  [PMC]
82. Park SS, Kim BC, Lee D eun, Han KS, Kim B, Hong CW, et al. Comparison of endoscopic submucosal dissection and transanal endoscopic microsurgery for T1 rectal neuroendocrine tumors: a propensity score-matched study. Gastrointest Endosc [Internet]. 2021;94(2):408-415.e2. [Crossref]  [PubMed]
83. Meier B, Albrecht H, Wiedbrauck T, Schmidt A, Caca K. Full-thickness resection of neuroendocrine tumors in the rectum. Endoscopy. 2020;52(1):68-72. [Crossref]  [PubMed]
84. Brand M, Reimer S, Reibetanz J, Flemming S, Kornmann M, Meining A. Endoscopic full thickness resection vs. transanal endoscopic microsurgery for local treatment of rectal neuroendocrine tumors a retrospective analysis. Int J Colorectal Dis. 2021;36(5):971-6. [Crossref]  [PubMed]  [PMC]
85. Cha B, Shin J, Ko WJ, Kwon KS, Kim H. Prognosis of incompletely resected small rectal neuroendocrine tumor using endoscope without additional treatment. BMC Gastroenterol. 2022;22(1):1-8. [Crossref]  [PubMed]  [PMC]
86. Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45(2):234-43. [Crossref]  [PubMed]
87. Hofland J, Falconi M, Christ E, Castaño JP, Faggiano A, Lamarca A, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):1-19. [Crossref]  [PubMed]
88. Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol. 2008;14(35):5377-84. [Crossref]  [PubMed]  [PMC]
89. Puli SR, Kalva N, Bechtold ML, Pamulaparthy SR, Cashman MD, Estes NC, et al. Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: A systematic review and meta analysis. World J Gastroenterol. 2013;19(23):3678-84. [Crossref]  [PubMed]  [PMC]
90. James PD, Tsolakis A V., Zhang M, Belletrutti PJ, Mohamed R, Roberts DJ, et al. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: A meta-analysis. Gastrointest Endosc [Internet]. 2015;81(4):848856.e1. [Crossref]  [PubMed]
91. Zhang B, Zhu F, Li P, Yu S, Zhao Y, Li M. Endoscopic ultrasound elastography in the diagnosis of pancreatic masses: A meta-analysis. Pancreatology [Internet]. 2018;18(7):833-40. [Crossref]  [PubMed]
92. Carrara S, Di Leo M, Grizzi F, Correale L, Rahal D, Anderloni A, et al. EUS elastography (strain ratio) and fractal-based quantitative analysis for the diagnosis of solid pancreatic lesions. Gastrointest Endosc [Internet]. 2018;87(6):1464-73. [Crossref]  [PubMed]
93. He XK, Ding Y, Sun LM. Contrast-enhanced endoscopic ultrasound for differential diagnosis of pancreatic cancer: An updated meta-analysis. Oncotarget. 2017;8(39):66392-401. [Crossref]  [PubMed]  [PMC]
94. Palazzo M, Napoléon B, Gincul R, Pioche M, Pujol B, Lefort C, et al. Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos). Gastrointest Endosc [Internet]. 2018;87(6):1481-8. [Crossref]  [PubMed]
95. Rimbas M, Larghi A, Fusaroli P, Dong Y, Hollerbach S, Jenssen C, et al. How to perform EUS-guided tattooing? Endosc Ultrasound. 2020;9(5):291-7. [Crossref]  [PubMed]  [PMC]
96. Melita G, Pallio S, Tortora A, Crinò SF, Macrì A, Dionigi G. Diagnostic and interventional role of endoscopic ultrasonography for the management of pancreatic neuroendocrine neoplasms. J Clin Med. 2021;10(12). [Crossref]  [PubMed]  [PMC]
97. Leeds JS, Nayar MK, Bekkali NLH, Wilson CH, Johnson SJ, Haugk B, et al. Endoscopic ultrasound-guided fine-needle biopsy is superior to fine-needle aspiration in assessing pancreatic neuroendocrine tumors. Endosc Int Open. 2019;07(10):E1281-7. [Crossref]  [PubMed]  [PMC]
98. Rimbaş M, Horumbă M, Rizzatti G, Crinò SF, Gasbarrini A, Costamagna G, et al. Interventional endoscopic ultrasound for pancreatic neuroendocrine neoplasms. Dig Endosc. 2020;32(7):1031-41. [Crossref]  [PubMed]
99. Paiella S, Salvia R, Ramera M, Girelli R, Frigerio I, Giardino A, et al. Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review. Gastroenterol Res Pract. 2016;2016. [Crossref]  [PubMed]  [PMC]
100. Imperatore N, de Nucci G, Mandelli ED, de Leone A, Zito FP, Lombardi G, et al. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature. Endosc Int Open. 2020;08(12):E1759-64. [Crossref]  [PubMed]  [PMC]
101. Choi JH, Park DH, Kim MH, Hwang HS, Hong SM, Song TJ, et al. Outcomes after endoscopic ultrasound-guided ethanol-lipiodol ablation of small pancreatic neuroendocrine tumors. Dig Endosc. 2018;30(5):652-8. [Crossref]  [PubMed]
102. Garg R, Mohammed A, Singh A, Harnegie M, Rustagi T, Stevens T, et al. EUS-guided radiofrequency and ethanol ablation for pancreatic neuroendocrine tumors: A systematic review and meta-analysis. Endosc Ultrasound. 2022;11(3):170-85. [Crossref]  [PubMed]  [PMC]
103. So H, Ko SW, Shin SH, Kim EH, Son J, Ha SH, et al. Comparison of EUS-guided ablation and surgical resection for nonfunctioning small pancreatic neuroendocrine tumors: a propensity score-matching study. Gastrointest Endosc [Internet]. 2023;97(4):741-751.e1. [Crossref]  [PubMed]
104. Sallinen VJ, Le Large TTY, Tieftrunk E, Galeev S, Kovalenko Z, Haugvik SP, et al. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors a multi-institutional study. Hpb [Internet]. 2018;20(3):251-9. [Crossref]  [PubMed]
105. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, et al. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020;49:1-33. [Crossref]  [PubMed]  [PMC]
106. Singh S, Dey C, Kennecke H, Kocha W, Maroun J, Metrakos P, et al. Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group. Ann Surg Oncol. 2015;22(8):2685-99. [Crossref]  [PubMed]